Loading... Please wait... Loading... Please wait...
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Its products also comprise instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Asensus Surgical (ASXC) announces an agreement with St. Marianna University School of Medicine Yokohama City Seibu Hospital to lease its Senhance Surgical System....
RESEARCH TRIANGLE PARK, N.C., June 24, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the pati...
KARL STORZ is set to acquire all of the outstanding shares of Asensus Surgical (ASXC) for $0.35 per share in cash, making Asensus a subsidiary of KARL STORZ....
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breac...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Asensus Surg...
NEW YORK , June 7, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securiti...
MILWAUKEE, June 7, 2024 /PRNewswire/ -- Ademi LLP is investigating Asensus Surgical (NYSE: ASXC) for possible breaches of fiduciary duty and other violations of law in its transaction with KARL STOR...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Asensus Surgical, Inc. (NYSE American: ASXC) to KARL STORZ Endoscopy-America, Inc. for $0...
KARL STORZ to acquire Asensus for $0.35 per share in cash Creating a leading surgical robotics division within KARL STORZ RESEARCH TRIANGLE PARK, N.C., June 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgic...
